Clinical trial · Interventional
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)
NCT00235482CI-TRIAL-00039243PXS-X02completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour, and also to see if there is a tumour response.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Melanoma | Melanoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Coxsackievirus A21 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Safety profile of treatment, characterisation of adverse events
Secondary outcomes (1)
- measure
- Efficacy - clinical response of injected and non-injected tumours
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * stage IV melanoma (AJCC classification) * minimum of 2 sc metastases * failure or refusal of standard chemotherapy * ECOG score of 0 or 1 * other Exclusion Criteria: * metastatic CNS disease * ocular or mucosal melanoma * immunodeficiency * splenectomy * other
References
Publications (0)
Data not yet available
No reference posted for this study.